ClinicalTrials.gg
Not yet recruitingNCT07938567PRESTOUpdated Nov 16, 2026

Preeclampsia Screening Trial to Improve Outcomes

An interventional study of Kryptor sFlt-1/PlGF assays on serum/plasma and Treatment in Pregnancy Related and Hypertensive Disorder of Pregnancy (HDP), sponsored by Emory University. Not yet recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Emory University · Not applicable, Interventional, and Diagnostic

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,000
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 230 studies in Pre-Eclampsia with a site in United States — 62 open to participants now, 78 under way, 6 of them phase 3. Pre-Eclampsia · United States.

Planned enrollment
9th of 161
1,000 · median 89
Started
2026
with 28 others
No phase
73 of 230
19 open now
Primary completion
2028-06
later than 54 of 77 live
Registered
229th of 230
by date

Among the 230 studies in Pre-Eclampsia with a site in United States, this one is the 9th largest by planned enrollment of the 161 interventional ones that give a count, is one of 29 that started in 2026, is one of 73 with no phase, reaches primary completion later than 54 of the 77 other live ones, and was the 229th registered.

Pre-Eclampsia

918 studies on the registry are indexed under Pre-Eclampsia; 244 are open to participants now.

Browse Pre-Eclampsia studies →

Open to participants now

62 of the 230 studies in Pre-Eclampsia with a site in United States are open now. Recruiting first, the newest first:

57 more — sign in →

All 62 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 162 Pre-Eclampsia studies recruiting now, 81 (50%) set no upper age limit and 80 (49%) stop at 75 or younger; 18 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 230 studies in Pre-Eclampsia with a site in United States, or all of them as a file.
02

Study summary

The Pre-eclampsia Screening Trial to Improve Outcomes (PRESTO) research study aims to assess how clinicians use a blood test to guide care decisions in determining preeclampsia risk, with the overall aim of improving outcomes for both pregnant persons and their babies.

The study will evaluate whether a blood test can help doctors better identify pregnant patients with hypertensive disorders of pregnancy who are at risk of developing severe pre-eclampsia, which is a serious pregnancy condition that can affect organs such as the liver and kidneys and often leads to preterm delivery. The lab test measures two naturally occurring proteins in the blood that help estimate short-term risk for worsening disease. The goal is to determine whether providing this lab test result to clinicians can improve outcomes including safely prolong pregnancy, reduce unnecessary preterm deliveries, improve newborn outcomes, and optimize hospital care, without increasing complications for pregnant women or causing excess risks to the baby.

Read the detailed description

Participants will receive standard clinical care and will have a small blood sample drawn for the lab test. This study will have two phases: Phase A - the pre-phase and Phase B- the post-phase. The difference in the phases is whether test results are shared with doctors. Depending on when their hospital enters the study and which phase they are enrolled in, clinicians may or may not receive the test result, allowing researchers to compare outcomes before and after use of the test. Enrolled participants in both phases will have a blood draw, and data will be collected about their pregnancy and delivery.

Participants assigned to Phase A - the control phase, will not have their lab results shared with their doctor and will receive standard care. Participants assigned to Phase B - the intervention phase, will have their lab results shared with their doctor. Following phase A but before phase B, clinicians will receive education on the blood test and clinical management.

Participation lasts from hospital enrollment through delivery and discharge. Newborns will not undergo study procedures, but information will be collected from their medical records for them. The blood samples from the single lab draw will be stored temporarily for study analysis only and will not be banked for future unspecified research. No experimental drugs will be administered.

03

Conditions studied

  • Pregnancy Related
  • Hypertensive Disorder of Pregnancy (HDP)

Browse trials for

Keywords

  • Blood test
  • Singleton Pregnancy
  • Pre-eclampsia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pregnant persons aged 18 years or older.
  • Singleton pregnancy.
  • Gestational age from 23 weeks 0 days through 33 weeks 6 days.
  • Presentation to obstetric triage or hospitalization for a hypertensive disorder of pregnancy.
  • Provision of signed (English- or Spanish-speaking).

Exclusion criteria

Exclusion Criteria:

  • Enrollment in another therapeutic interventional trial with a primary outcome of HDP
  • Receipt of intravenous heparin during hospitalization.
  • Planned delivery upon admission for HDP within 48 hours of admission (If a patient is admitted with no immediate plan for delivery, but then a delivery decision is made, patients will still be included and analyzed accordingly)
  • Prior study enrollment during the current pregnancy.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
1,000 participants (estimated)

Study arms

  • Active comparator
    Blinded Test Results (Phase A)

    Patients will be enrolled upon admission to the Labor \& Delivery/Maternity or antepartum units. Triage units will be considered part of Labor \& Delivery for this study. Management proceeds per local standard of care. Blood samples for sFlt-1/PlGF measurement will be collected and stored for later analysis; however, test results will remain blinded to clinicians and will not be available to guide clinical management during this phase. Biomarker measurements will be analyzed retrospectively for research purposes.

    Device: Kryptor sFlt-1/PlGF assays on serum/plasma

  • Experimental
    Real Time Results (Phase B)

    Patients will be enrolled upon admission to the Labor \& Delivery/Maternity or antepartum units. Triage units will be considered part of Labor \& Delivery for this study. During the Intervention phase (post-implementation), results are reported in real time (within 24 hours) to treating clinicians. Management proceeds per the treating clinician, who has been educated to use the FDA-approved algorithm for the use of the test.

    Device: Kryptor sFlt-1/PlGF assays on serum/plasma · Other: Treatment

Interventions

  • DeviceKryptor sFlt-1/PlGF assays on serum/plasma

    Serum sFlt-1/PlGF biomarker, authorized by the U.S. Food and Drug Administration for use in pregnant patients with hypertensive disorders of pregnancy from 23+0 through 33+6 weeks of gestation.

    Also known as: Plasma sFlt-1/PlGF biomarker, Preclara

  • OtherTreatment

    sFlt-1/PlGF measurements will be available to clinicians in real time and may be incorporated into clinical management according to the FDA-approved algorithm

06

What researchers measure

Primary outcomes

  1. Pregnancy latency

    Time from admission to delivery

    Time frame: At delivery (up to 40 weeks of gestation)

  2. Participants with maternal adverse outcomes

    The number of participants who experience one or more of the following maternal adverse events: cerebral hemorrhage, seizures (eclampsia), pulmonary edema, disseminated intravascular coagulation (DIC), new onset acute renal failure (creatinine \> 1.4), peripartum cardiomyopathy, ischemic stroke, or HELLP syndrome \[doubling of liver function test (LFT) and platelets count\<100,000\] or severe hypertension that required a parenteral infusion of a third-line antihypertensive.

    Time frame: From enrollment until post-natal discharge (on average 10 days post-delivery)

Secondary outcomes

  1. Number of participants who require hospital admission

    Number of participants who require hospital admission during study participation, collected form medical records.

    Time frame: From enrollment up to 37 weeks of gestation

  2. Number of participants with indicated delivery within 14 days of presentation

    Participants who require delivery within 14 days of presentation

    Time frame: Up to 14 days from enrollment

  3. Number of participants who require transfer to tertiary care centers

    Participants who require transfer to tertiary care centers as documented in the medical records.

    Time frame: From enrollment until post-natal hospital discharge (on average 10 days post-delivery)

  4. Number of participants who received antenatal corticosteroid administration

    Participants who receive antenatal corticosteroid administration as documented in the medical records.

    Time frame: Between 24 weeks and 34 weeks of gestation

  5. Number of preterm births less than 37 weeks

    Preterm births at \<37 weeks' gestation between the pre-implementation and post-implementation periods.

    Time frame: From enrollment up to 36 weeks and 6 days of pregnancy

  6. Number of early preterm births

    Early preterm births at \<32 weeks' gestation between the pre-implementation and post-implementation periods. Analyses of preterm birth \<32 weeks will be restricted to individuals enrolled before 32 weeks' gestation.

    Time frame: From enrollment up to 31 weeks and 6 days of pregnancy

  7. Composite Adverse Fetal/Neonatal Outcomes

    Composite outcome defined as the occurrence of one or more of the following fetal or neonatal adverse events: fetal or neonatal death, low birth weight (\<2500 g), respiratory distress syndrome (RDS), bronchopulmonary dysplasia, retinopathy of prematurity, necrotizing enterocolitis, or grade III/IV intraventricular hemorrhage. The proportion of participants experiencing the composite outcome will be compared between the intervention and control groups.

    Time frame: From maternal enrollment through 28 days after birth

  8. Length of hospital admission (mother's) of stay,

    Length of hospital admission, extracted from medical records

    Time frame: From admission until post-natal hospital discharge (on average 10 days post-delivery)

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — Individual de-identified participant data may be made available upon reasonable request, subject to Sponsor review. The specific data to be shared will be determined based on the Sponsor's review of the requested data and the nature of the request.

Supporting information: Study protocol

Time frame: No specific end date has been established.

Access criteria: Requests will be reviewed by the Research Team, and approved data will be shared through a method determined Requests will be reviewed by the Sponsor, and approved data will be shared through an appropriate method determined at the time of approval. Data will be shared with the Qualified researchers or organizations whose requests are approved by the Sponsor. Contingent upon the Sponsor's approved data request.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Jun 2028, 18 months later.

Of 171 non-industry interventional studies with no phase under Pre-Eclampsia, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 43. This study's planned 18 months is below that.

Counting every sponsor, half of 176 studies reached it within 24 months; a quarter within 9 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 14, 2026
First posted
Nov 16, 2026
StartEst.
Dec 2026
Primary completionEst.
Jun 2028
CompletionEst.
Jun 2028
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07938567
Lead sponsor
Emory University
Responsible party
Suchitra Chandrasekaran (Associate Professor, Emory University) — Principal investigator
First posted
Nov 16, 2026
Start date
Dec 2026 (estimated)
Primary completion
Jun 2028 (estimated)
Completion
Jun 2028 (estimated)
Last update
Nov 16, 2026

Study contacts

Tae Stallworth
Contact
tae.stallworth@emory.edu
770-742-8942 |
Suchitra Chandrasekaran, MD
principal investigator · Emory University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion